“Gene editing of primary human cells using Scalable Transfection Systems ”

Please join us in welcoming MaxCyte, Inc. to NHLBI to present their technology for high quality and efficient gene editing of primary human cells.

MaxCyte, Inc. is the provider of Scalable Transfection Systems to cell-engineering of primary human cells from early research to commercial manufacturing.  The system is closed, computer-controlled instruments that are cGMP-compliant, ISO-certified, CE-marked, and based on Flow Electroporation™ Technology with seamless scalability.

MaxCyte, Inc

Monday, September 10th, 2018

12:15 PM – 2:00 PM

2nd Floor Hatfield Conference Room 2-3330

Building 10-CRC

Categories: Uncategorized